Matches in Nanopublications for { <http://www.w3.org/2000/01/rdf-schema#SENTENCE> ?p ?o ?g. }
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The PK model of dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) as well as that of dexamethasone (DEX) with a time-dependent clearance were integrated into the final PK/PD model both using Hill’s function, where dexamethasone (DEX) exerted dexamethasone (DEX)'s antitumor efficacy by inhibiting the proliferation of tumor cells, and dopamine D(2)-like receptor (D2DR) antagonist sulpiride (SUL) enhanced dexamethasone (DEX) responses by decreasing the sensitivity parameter EC(50)." provenance.
- SENTENCE label "The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and The dexamethasone is shown in a randomized clinical trial by the United Kingdom that The dexamethasone reduced the death rate in The coronavirus disease 2019 (COVID)-19) patients." provenance.
- SENTENCE label "The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and The dexamethasone is shown in a randomized clinical trial by the United Kingdom that The dexamethasone reduced the death rate in The coronavirus disease 2019 (COVID)-19) patients." provenance.
- SENTENCE label "The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and The dexamethasone is shown in a randomized clinical trial by the United Kingdom that The dexamethasone reduced the death rate in The coronavirus disease 2019 (COVID)-19) patients." provenance.
- SENTENCE label "The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and The dexamethasone is shown in a randomized clinical trial by the United Kingdom that The dexamethasone reduced the death rate in The coronavirus disease 2019 (COVID)-19) patients." provenance.
- SENTENCE label "The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and The dexamethasone is shown in a randomized clinical trial by the United Kingdom that The dexamethasone reduced the death rate in The coronavirus disease 2019 (COVID)-19) patients." provenance.
- SENTENCE label "The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and The dexamethasone is shown in a randomized clinical trial by the United Kingdom that The dexamethasone reduced the death rate in The coronavirus disease 2019 (COVID)-19) patients." provenance.
- SENTENCE label "The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and The dexamethasone is shown in a randomized clinical trial by the United Kingdom that The dexamethasone reduced the death rate in The coronavirus disease 2019 (COVID)-19) patients." provenance.
- SENTENCE label "The dexamethasone is a first known steroid medicine that can save the lives of seriously ill patients, and The dexamethasone is shown in a randomized clinical trial by the United Kingdom that The dexamethasone reduced the death rate in The coronavirus disease 2019 (COVID)-19) patients." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Corticosteroid treatment with dexamethasone has been shown to reduce mortality in COVID-19 patients in hospital, through the Recovery Trial." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "Urgent and elective surgical procedures and intravitreal injections of anti-VEGF drugs or dexamethasone reduced significantly in 2020 in comparison to 2019 (p < 0.0001 for urgent and elective surgeries and 0.01 for intravitreal injections)." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.
- SENTENCE label "After attachment in Ham’s nutrient mixture F12, Isolated acinar cells were cultured at 35°C in Ham’s nutrient mixture F12 supplemented with 10% heat inactivated rat serum, epidermal growth factor, dexamethasone, insulin, transferrin, selenium, putrescine, reduced glutathione, ascorbate, penicillin, streptomycin, and the appropriate secretagogue." provenance.